ROS-Responsive Cationic Nanoparticles for Cyclosporine A Delivery in Dry Eye Disease: A Dual-Functional Nanotherapeutic Approach
Lists
Only you see this
Abstract
Dry eye disease (DED) is a prevalent ocular surface disorder characterized by tear film instability, chronic inflammation, and oxidative stress affecting 10-30% of the global population. A key driver of DED pathogenesis is the excessive reactive oxygen species (ROS), which disrupts corneal epithelial integrity, triggers apoptosis, and leads to a vicious cycle of inflammation and tissue damage. Current DED treatment involves immunosuppressants including cyclosporine A (CsA). However, conventional cyclosporine A (CsA) formulations suffer from poor solubility, rapid clearance, and nontargeted release. To address this problem, we developed CsA-loaded cationic nanoparticles (NPs) by coassembly of CsA with a cationic amphiphilic alternating copolymer P-(MS-<i>a</i>-EG), which could undergo a transition from amphiphilic to hydrophilic upon ROS exposure, thereby facilitating the release of cargo. The obtained CsA@P-(MS-<i>a</i>-EG) NPs exhibited prolonged ocular retention due to electrostatic interactions with the anionic ocular surfaces. In the DED mice model, CsA@P-(MS-<i>a</i>-EG) NPs effectively restored tear secretion, improved tear film stability, and promoted the recovery of corneal epithelium with normalized thickness. Furthermore, the nanoparticles exhibited excellent biosafety, with no observed systemic toxicity. This dual-functional nanoplatform combines a cationic polymer functionalized for ROS-responsive release and corneal adhesion with CsA for DED therapy, offering a targeted and patient-friendly strategy.
BibTeX
@inproceedings{wang2025ros,
author = {Pingping Wang and Guanchun Wang and Xiangling Liu},
title = {{ROS-Responsive Cationic Nanoparticles for Cyclosporine A Delivery in Dry Eye Disease: A Dual-Functional Nanotherapeutic Approach}},
booktitle = {ACS},
year = {2025},
doi = {10.1021/acsomega.5c07414},
}Loading related content...